Please ensure Javascript is enabled for purposes of website accessibility

Novavax loss increases

Novavax Inc., of Gaithersburg, a biopharmaceutical company focused on creating vaccines, reported higher revenues but an increased loss for the third quarter. Novavax’s net loss was $19.7 million, or 8 cents per share, for the quarter, compared with a net loss of $15.3 million, or 9 cents, for same period in 2013. Revenue in the 2014 third quarter increased 71 percent to $8.2 million, compared with $4.8 million for 2013’s quarter. Novavax said the increase was primarily due to clinical trials for two flu vaccine candidates.